Regenxbio（NASDAQ:RGNX）報告季度每股虧損$(1.01)，優於分析師預期的$(1.15)，提高了12.17%。這一數字比去年同期每股虧損$(1.43)增長了29.37%。公司報告季度銷售額爲2121萬美元，低於分析師預期的2375萬美元，減少了10.69%。這一數字比去年同期的2221萬美元減少了4.50%。

以上內容來自Benzinga Earnings專欄，原文如下：

Regenxbio (NASDAQ:RGNX) reported quarterly losses of $(1.01) per share which beat the analyst consensus estimate of $(1.15) by 12.17 percent. This is a 29.37 percent increase over losses of $(1.43) per share from the same period last year. The company reported quarterly sales of $21.21 million which missed the analyst consensus estimate of $23.75 million by 10.69 percent. This is a 4.50 percent decrease over sales of $22.21 million the same period last year.